{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:44:21Z","timestamp":1775627061775,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>According to the NAPOLI-1 trial, nanoliposomal irinotecan (nal-IRI) plus fluorouracil\/folinic acid (5-FU\/LV) showed improved overall survival compared to fluorouracil alone for patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapy. In that trial, Asian patients had frequent dose modification due to haematological toxicity. There has been limited information on the clinical benefits and toxicity of this regimen in real-world settings. In this study, we assessed real-world experience of nal-IRI plus 5-FU\/LV in patients with advanced pancreatic cancer after gemcitabine failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a single institution, retrospective analysis of response, survival and safety in patients who had been treated with nal-IRI with 5-FU\/LV. Patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy received nal-IRI (80\u2009mg\/m<jats:sup>2<\/jats:sup>) with 5-FU\/LV every 2\u2009weeks. Kaplan-Meier analysis was performed to obtain median progression free survival and median overall survival. The hazard ratio and 95% confidence interval (CI) were estimated using a stratified Cox regression model. A multivariate Cox proportional hazards regression model was used to identify the effects of clinical factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty-one patients received nal-IRI plus 5-FU\/LV between January 2015 and December 2020. The median age was 67\u2009years, and males were 58.8%. A total of 40 (78.4%) and 11 (21.6%) patients had received one and two lines of prior chemotherapy before enrollment, respectively. Median progression-free survival was 2.8\u2009months (95% CI 1.8\u20133.7) and median overall survival was 7.0\u2009months (95% CI 6.0\u20137.9). Chemotherapy doses were reduced or delayed in 33 (64.7%) patients during the first 6\u2009weeks and median relative dose intensity was 0.87. Thirty-six (70.6%) patients experienced grade 3 or 4 adverse events, most commonly neutropenia (58.8%). Most non-haematologic adverse events were under grade 2. Since the start of first-line chemotherapy, median overall survival was 16.3\u2009months (95% CI 14.1\u201318.4).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Nal-IRI plus 5-FU\/LV seems to be effective, with manageable toxicities, following gemcitabine-based treatment in patients with metastatic pancreatic ductal adenocarcinoma. Nal-IRI plus 5-FU\/LV following gemcitabine with nab-paclitaxel is a feasible sequential treatment option in patients with metastatic pancreatic cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08887-1","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T17:16:42Z","timestamp":1635959802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5486-9818","authenticated-orcid":false,"given":"Se Jun","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1276-713X","authenticated-orcid":false,"given":"Hyunho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6709-0894","authenticated-orcid":false,"given":"Kabsoo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-8104","authenticated-orcid":false,"given":"Tae Ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1423-2139","authenticated-orcid":false,"given":"Ja Hee","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1204-0574","authenticated-orcid":false,"given":"Myung Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"issue":"44","key":"8887_CR1","doi-asserted-by":"publisher","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","volume":"22","author":"M Ilic","year":"2016","unstructured":"Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694\u2013705. https:\/\/doi.org\/10.3748\/wjg.v22.i44.9694.","journal-title":"World J Gastroenterol"},{"issue":"17","key":"8887_CR2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605\u201317. https:\/\/doi.org\/10.1056\/NEJMra0901557.","journal-title":"N Engl J Med"},{"key":"8887_CR3","volume-title":"American cancer society: Cancer facts and figures","author":"V Cokkinides","year":"2005","unstructured":"Cokkinides V, Albano J, Samuels A, Ward M, Thum J. American cancer society: Cancer facts and figures. American Cancer Society: Atlanta; 2005."},{"issue":"19","key":"8887_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"issue":"18","key":"8887_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"issue":"11","key":"8887_CR6","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.7150\/jca.23716","volume":"9","author":"AM Mart\u00edn","year":"2018","unstructured":"Mart\u00edn AM, Hidalgo M, Alvarez R, Arrazubi V, Mart\u00ednez-Gal\u00e1n J, Salgado M, et al. From first line to sequential treatment in the management of metastatic pancreatic cancer. J Cancer. 2018;9(11):1978\u201388. https:\/\/doi.org\/10.7150\/jca.23716.","journal-title":"J Cancer"},{"issue":"4","key":"8887_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(4):439\u201357. https:\/\/doi.org\/10.6004\/jnccn.2021.0017.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"8887_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-5244-2","volume":"19","author":"H Blomstrand","year":"2019","unstructured":"Blomstrand H, Scheibling U, Bratth\u00e4ll C, Green H, Elander NO. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer. 2019;19(1):1\u20139. https:\/\/doi.org\/10.1186\/s12885-018-5244-2.","journal-title":"BMC Cancer"},{"issue":"23","key":"8887_CR9","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","volume":"74","author":"AV Kalra","year":"2014","unstructured":"Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC, et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014;74(23):7003\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0572.","journal-title":"Cancer Res"},{"issue":"10018","key":"8887_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(15)00986-1.","journal-title":"Lancet"},{"issue":"1","key":"8887_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4605-1","volume":"18","author":"DC Glassman","year":"2018","unstructured":"Glassman DC, Palmaira RL, Covington CM, Desai AM, Ku GY, Li J, et al. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer. 2018;18(1):1\u201310. https:\/\/doi.org\/10.1186\/s12885-018-4605-1.","journal-title":"BMC Cancer"},{"key":"8887_CR12","doi-asserted-by":"publisher","first-page":"175883591985319","DOI":"10.1177\/1758835919853196","volume":"11","author":"M Kieler","year":"2019","unstructured":"Kieler M, Unseld M, Bianconi D, Scheithauer W, Prager GW. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. Ther Adv Med Oncology. 2019;11:1758835919853196. https:\/\/doi.org\/10.1177\/1758835919853196.","journal-title":"Ther Adv Med Oncology"},{"issue":"3","key":"8887_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","volume":"93","author":"LJ Havrilesky","year":"2015","unstructured":"Havrilesky LJ, Reiner M, Morrow PK, Watson H, Crawford J. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol. 2015;93(3):203\u201310. https:\/\/doi.org\/10.1016\/j.critrevonc.2014.10.006.","journal-title":"Crit Rev Oncol Hematol"},{"key":"8887_CR14","doi-asserted-by":"publisher","first-page":"175883591987112","DOI":"10.1177\/1758835919871126","volume":"11","author":"C Yoo","year":"2019","unstructured":"Yoo C, Im H-S, Kim K-P, Oh D-Y, Lee K-H, Chon HJ, et al. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil\/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Ther Adv Med Oncol. 2019;11:1758835919871126. https:\/\/doi.org\/10.1177\/1758835919871126.","journal-title":"Ther Adv Med Oncol"},{"key":"8887_CR15","doi-asserted-by":"publisher","first-page":"viii250","DOI":"10.1093\/annonc\/mdy282.117","volume":"29","author":"L-T Chen","year":"2018","unstructured":"Chen L-T, Macarulla T, Blanc J, Mirakhur B, de Jong F, Belanger B, et al. Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+ 5-fluorouracil\/leucovorin (5-FU\/LV): Survival analysis from NAPOLI-1. Annals of Oncology. 2018;29:viii250\u2013viii1.","journal-title":"Annals of Oncology"},{"issue":"2","key":"8887_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/cas.14264","volume":"111","author":"YJ Bang","year":"2020","unstructured":"Bang YJ, Li CP, Lee KH, Chiu CF, Park JO, Shan YS, et al. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: subgroup analysis of the NAPOLI-1 study. Cancer Sci. 2020;111(2):513\u201327. https:\/\/doi.org\/10.1111\/cas.14264.","journal-title":"Cancer Sci"},{"key":"8887_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","volume":"108","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.007.","journal-title":"Eur J Cancer"},{"issue":"6","key":"8887_CR18","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cpt.720","volume":"102","author":"B Adiwijaya","year":"2017","unstructured":"Adiwijaya B, Kim J, Lang I, Cs\u00f5szi T, Cubillo A, Chen JS, et al. Population pharmacokinetics of liposomal irinotecan in patients with cancer. Clin Pharmacol Ther. 2017;102(6):997\u20131005. https:\/\/doi.org\/10.1002\/cpt.720.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"8887_CR19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1634\/theoncologist.2016-0447","volume":"22","author":"TA Abrams","year":"2017","unstructured":"Abrams TA, Meyer G, Meyerhardt JA, Wolpin BM, Schrag D, Fuchs CS. Patterns of chemotherapy use in a US-based cohort of patients with metastatic pancreatic cancer. Oncologist. 2017;22(8):925\u201333. https:\/\/doi.org\/10.1634\/theoncologist.2016-0447.","journal-title":"Oncologist"},{"issue":"4","key":"8887_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000453257","volume":"94","author":"N Le","year":"2016","unstructured":"Le N, Vinci A, Schober M, Krug S, Javed MA, Kohlmann T, et al. Real-world clinical practice of intensified chemotherapies for metastatic pancreatic cancer: results from a pan-european questionnaire study. Digestion. 2016;94(4):222\u20139. https:\/\/doi.org\/10.1159\/000453257.","journal-title":"Digestion."},{"issue":"7","key":"8887_CR21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/bjc.2015.328","volume":"113","author":"A Portal","year":"2015","unstructured":"Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, De La Fouchardi\u00e8re C, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015;113(7):989\u201395. https:\/\/doi.org\/10.1038\/bjc.2015.328.","journal-title":"Br J Cancer"},{"issue":"6","key":"8887_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/jcm8060761","volume":"8","author":"N Mita","year":"2019","unstructured":"Mita N, Iwashita T, Uemura S, Yoshida K, Iwasa Y, Ando N, et al. Second-line gemcitabine plus nab-paclitaxel for patients with unresectable advanced pancreatic cancer after first-line FOLFIRINOX failure. J Clin Med. 2019;8(6):761. https:\/\/doi.org\/10.3390\/jcm8060761.","journal-title":"J Clin Med"},{"key":"8887_CR23","doi-asserted-by":"crossref","unstructured":"Ramanathan RK, Lee P, Seng JE, Anthony SP, Rosen PJ, Mena RR, Picozzi VJ, Sachdev JC, Larson T, Korn R: Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer. In.: American Society of Clinical Oncology; 2014.","DOI":"10.1200\/jco.2014.32.3_suppl.224"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08887-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08887-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08887-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T17:19:22Z","timestamp":1635959962000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08887-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8887"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08887-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,3]]},"assertion":[{"value":"2 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were performed in accordance with Korean regulations and the Declaration of Helsinki. This study was approved by the Institutional Review Board (IRB) of The Catholic University of Korea, Seoul St. Mary\u2019s Hospital (approval ID: KC21RISI0198) with a waiver of informed consent due to the retrospective nature of the analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1176"}}